title: Treatment of orthopedic infections caused by resistant staphylococci.
abstract: During 1999-2005 we treated 15 patients with linezolid for relevant infections of locomotion apparatus (7 cases with endoprosthesis infection, 5x osteomyelitis and 3x another infection). With the exception of one case the antibiotic therapy was always combined with appropriate surgical intervention. Average period of linezolid administration was 26 d; linezolid was applied from the beginning intravenously on average for 10 d, and then orally for 16 d (average). There were no undesirable effects in the file. Success rate reached 86.6%. MRSA strains were proved by standard methods: growth on Mueller-Hinton agar with increased concentration of NaCl and 2 mg/L of oxacilline, and measuring inhibitory zones around cephoxitine disk. The sensitivity to other antibiotics was specified by disk-diffusion test; that to linezolid was verified by E-test. Linezolid represents a medical reserve for the treatment of multiresistant Gram-positive infections or for emergencies, when allergy onset, high toxicity risk, intolerance, etc. do not allow to use other, in vitro effective, antibiotics.
authors: 1st Orthopedic Clinic, 1st Medical Faculty, Charles University, 150 06 Prague, Czechia. david.jahoda@post.cz
authors: D
authors: D
authors: Jahoda
authors: O
authors: O
authors: Nyc
authors: D
authors: D
authors: Pokorný
authors: I
authors: I
authors: Landor
authors: T
authors: T
authors: Krůta
authors: A
authors: A
authors: Sosna
mesh_terms: D000081:Acetamides / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069349:Linezolid; D008297:Male; D016106:Methicillin Resistance / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010019:Osteomyelitis / Q000188:drug therapy* / Q000382:microbiology; D023303:Oxazolidinones / Q000627:therapeutic use*; D016459:Prosthesis-Related Infections / Q000188:drug therapy* / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects*; D016896:Treatment Outcome
chemical_list: D000081:Acetamides; D000890:Anti-Infective Agents; D023303:Oxazolidinones; D000069349:Linezolid
references: Antimicrob Agents Chemother. 2003 Dec;47(12):3964-6
references: 14638510
references: Lancet. 2001 Jul 21;358(9277):207-8
references: 11476839
references: Clin Microbiol Infect. 2005 Jul;11 Suppl 4:33-42
references: 15997484
references: Lancet. 2001 Apr 14;357(9263):1179
references: 11323048
references: Antimicrob Agents Chemother. 2005 Jun;49(6):2260-6
references: 15917519
references: Curr Opin Investig Drugs. 2005 Feb;6(2):185-90
references: 15751742
references: Mayo Clin Proc. 2004 Sep;79(9):1137-44
references: 15357035
references: J Antimicrob Chemother. 2002 Jul;50(1):73-7
references: 12096009
references: Am J Surg. 2004 Dec;188(6):760-6
references: 15619496
references: Antimicrob Agents Chemother. 2000 Dec;44(12):3408-13
references: 11083648
references: BMJ. 2000 Jan 22;320(7229):213-6
references: 10642227
references: Folia Microbiol (Praha). 2006;51(5):381-6
references: 17176756
references: Expert Opin Drug Saf. 2004 Sep;3(5):405-14
references: 15335296
references: Folia Microbiol (Praha). 2005;50(3):187-94
references: 16295655
references: Folia Microbiol (Praha). 2006;51(3):236-8
references: 17004656
references: Curr Opin Infect Dis. 2003 Dec;16(6):515-9
references: 14624099
references: Antimicrob Agents Chemother. 1998 Dec;42(12):3251-5
references: 9835522
references: J Mol Biol. 1999 Nov 19;294(1):93-101
references: 10556031
references: Ann Pharmacother. 2004 Jun;38(6):986-8
references: 15113981
references: Clin Orthop Relat Res. 2004 Oct;(427):67-71
references: 15552139
references: Infection. 2004 Feb;32(1):8-14
references: 15007736
references: J Antimicrob Chemother. 2005 Mar;55(3):387-90
references: 15705640
references: Clin Infect Dis. 1997 Apr;24(4):584-602
references: 9145732